Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

医学 吉西他滨 内科学 双盲 安慰剂 肿瘤科 随机对照试验 化疗 病理 替代医学
作者
Caicun Zhou,Lin Wu,Yun Fan,Zhehai Wang,Lianke Liu,Gongyan Chen,Li Zhang,Dingzhi Huang,Shundong Cang,Zhixiong Yang,Jianying Zhou,Chengzhi Zhou,Baolan Li,Juan Li,Min Fan,Jiuwei Cui,Yuping Li,Hui Zhao,Jian Fang,Jianxin Xue
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:16 (9): 1501-1511 被引量:224
标识
DOI:10.1016/j.jtho.2021.04.011
摘要

IntroductionThe standard chemotherapy for squamous NSCLC (sqNSCLC) includes platinum plus gemcitabine. Sintilimab, an anti–programmed cell death protein 1 antibody, plus platinum and gemcitabine (GP) has revealed encouraging efficacy as first-line therapy for sqNSCLC in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to further compare the efficacy and safety of sintilimab with placebo, both in combination with GP.MethodsORIENT-12, a randomized, double-blind, phase 3 study, was conducted at 42 centers in the People’s Republic of China (ClinicalTrials.gov, number NCT03629925). Patients with locally advanced or metastatic sqNSCLC and without EGFR-sensitive mutations or ALK rearrangements were enrolled in the study. The stratification factors included clinical stage, choice of platinum, and programmed death-ligand 1 tumor proportion score. The patients, investigators, research staff, and sponsor team were masked to treatment assignment. Eligible patients were randomized 1:1, using an integrated web-response system, to receive sintilimab 200 mg or placebo plus GP every 3 weeks for four or six cycles, followed by sintilimab or placebo as maintenance therapy until disease progression or 2 years. The primary end point was progression-free survival (PFS), assessed by an independent radiographic review committee.ResultsBetween September 25, 2018 and July 26, 2019, a total of 543 patients were screened, of whom 357 patients were randomized to the sintilimab-GP group (n = 179) and the placebo-GP group (n = 178). After a median follow-up period of 12.9 months, sintilimab-GP continued to reveal a meaningful improvement in PFS than placebo-GP (hazard ratio = 0.536 [95% confidence interval: 0.422–0.681], p < 0.00001). Treatment-emergent adverse events of grade 3 or worse occurred in 86.6% patients in the sintilimab-GP group and in 83.1% in the placebo-GP group. The incidence of treatment-emergent adverse event leading to death was 4.5% and 6.7% in the two treatment groups, respectively.ConclusionsRegarding PFS, sintilimab plus GP reveals clinical benefit than GP alone as first-line therapy in patients with locally advanced or metastatic sqNSCLC. The toxicity was acceptable, and no new unexpected safety signals were observed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科研通AI2S应助momo采纳,获得10
2秒前
内向连碧发布了新的文献求助10
4秒前
SaiKerry发布了新的文献求助10
5秒前
6秒前
ding应助菜菜采纳,获得10
7秒前
8秒前
高大的蜡烛完成签到,获得积分10
9秒前
10秒前
10秒前
hsuan风向仪完成签到,获得积分10
11秒前
神勇契完成签到,获得积分10
11秒前
pokexuejiao完成签到,获得积分10
11秒前
shore发布了新的文献求助10
11秒前
爆米花应助yufei采纳,获得10
12秒前
微笑宛儿完成签到,获得积分10
12秒前
菜菜完成签到,获得积分20
12秒前
充电宝应助帅男采纳,获得10
13秒前
_Y_X_L_发布了新的文献求助10
15秒前
研友_qZ6V1Z发布了新的文献求助10
15秒前
16秒前
anan_0528完成签到 ,获得积分10
17秒前
风清扬应助内向连碧采纳,获得10
18秒前
风清扬应助帅男采纳,获得10
19秒前
Annie发布了新的文献求助10
21秒前
21秒前
小蘑菇应助金不换采纳,获得10
22秒前
科研通AI2S应助momo采纳,获得10
22秒前
zyyin发布了新的文献求助10
25秒前
28秒前
紫菜完成签到,获得积分20
29秒前
Annie完成签到,获得积分20
31秒前
Hanayu完成签到 ,获得积分10
32秒前
今后应助phoenix采纳,获得10
32秒前
万能图书馆应助杉杉采纳,获得10
32秒前
金不换发布了新的文献求助10
33秒前
Transition完成签到,获得积分10
33秒前
33秒前
热心市民小红花应助MHM采纳,获得10
34秒前
36秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989797
求助须知:如何正确求助?哪些是违规求助? 3531910
关于积分的说明 11255394
捐赠科研通 3270563
什么是DOI,文献DOI怎么找? 1805008
邀请新用户注册赠送积分活动 882157
科研通“疑难数据库(出版商)”最低求助积分说明 809190